You are here

  • Home
  • Archive
  • Volume 9, Issue Suppl 2
  • 366 Combined exploratory immunophenotyping and transcriptomic tumor analysis in patients treated with OSE2101 vaccine in HLA-A2+ advanced non-small cell lung cancer (NSCLC) from the ATALANTE-1 trial

Article metrics

Article menu

Download PDFPDF

Regular and Young Investigator Award Abstracts
Clinical Trials Completed
366 Combined exploratory immunophenotyping and transcriptomic tumor analysis in patients treated with OSE2101 vaccine in HLA-A2+ advanced non-small cell lung cancer (NSCLC) from the ATALANTE-1 trial
Free

 

Online download statistics by month:

Online download statistics by month: November 2021 to August 2024

AbstractFullPdf
Nov 2021383027
Dec 20216602
Jan 20226809
Feb 20225402
Mar 202223403
Apr 20224606
May 202256016
Jun 20223209
Jul 20222403
Aug 20223804
Sep 20224204
Oct 20224608
Nov 202260012
Dec 20226007
Jan 20237007
Feb 20237208
Mar 20236207
Apr 20233605
May 20235809
Jun 202334014
Jul 202340013
Aug 20233404
Sep 202314407
Oct 20234406
Nov 20235407
Dec 20235805
Jan 20242802
Feb 20244603
Mar 20245208
Apr 20244008
May 202438015
Jun 20244902
Jul 20243606
Aug 20241804
Total22220252